###begin article-title 0
###xml 109 117 <span type="species:ncbi:9606">patients</span>
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1</italic>
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 307 315 307 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 259 264 <span type="species:ncbi:9606">women</span>
Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 168 171 168 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th </sup>
###xml 245 252 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1</italic>
###xml 42 47 <span type="species:ncbi:9606">women</span>
We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4th month by World Health Organization (WHO) criteria. Three polymorphisms of CYP19A1, one in exon 7 (rs700519) and two in the 3'-UTR region (rs10046 and rs4646) were evaluated on DNA obtained from peripheral blood.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 12 17 <span type="species:ncbi:9606">women</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 411 419 <span type="species:ncbi:9606">patients</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
###xml 644 652 <span type="species:ncbi:9606">patients</span>
Thirty-five women (36.8%) achieved a radiological response to letrozole. The histopathological and immunohistochemical parameters, including hormonal receptor status, were not associated with the response to letrozole. Only the genetic variants (AC/AA) of the rs4646 polymorphism were associated with poor response to letrozole (p = 0.03). Eighteen patients (18.9%) reported a progression of the disease. Those patients carrying the genetic variants (AC/AA) of rs4646 presented a lower progression-free survival than the patients homozygous for the reference variant (p = 0.0686). This effect was especially significant in the group of elderly patients not operated after letrozole induction (p = 0.009).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
Our study reveals that the rs4646 polymorphism identifies a subgroup of stage II-III ER/PgR [+] BC patients with poor response to neoadjuvant letrozole and poor prognosis. Testing for the rs4646 polymorphism could be a useful tool in order to orientate the treatment in elderly BC patients.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 801 802 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
After cessation of ovarian activity at postmenopause, the aromatase [cytochrome P450 19 (CYP19); OMIM:107910] from bones, adipose tissue and muscle, becomes the key enzyme in estradiol and estrone biosynthesis through the aromatization of testosterone and androstenedione respectively [1]. Aromatase is encoded by CYP19A1 which maps at chromosome 15q21.1 and has a complex structure with a region that contains 10 tissue-specific non-coding upstream exons with separate promoters that regulate transcription in different cells and tissues [2]. Elevated levels of aromatase expression have been observed in breast tumors relative to normal breast tissue [3], and alterations in aromatase expression have been implicated in the pathogenesis of estrogen-dependent diseases, including breast cancer (BC) [4,5].
###end p 10
###begin p 11
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 661 666 <span type="species:ncbi:9606">women</span>
The major biological characteristic of BC is that two thirds of cases express estrogen (ER) and/or progesterone receptors (PgR) [2,6,7], endocrine manipulation being an effective treatment for these patients. Tamoxifen, a selective ER modulator, has for decades been the gold standard therapy in ER/PgR [+] BC patients [8]. However, in postmenopausal patients, aromatase inhibitors like letrozole have consistently demonstrated to be more effective than tamoxifen [9]. Letrozole is highly specific for the aromatase enzyme and inhibits whole-body aromatization of almost 99%, providing a highly and essentially complete withdrawal of estrogen in postmenopausal women [10].
###end p 11
###begin p 12
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 67 72 <span type="species:ncbi:9606">women</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 651 658 <span type="species:ncbi:9606">patient</span>
Neoadjuvant hormonal therapy is a safety option for postmenopausal women with large operable or locally advanced hormone sensitive BC, increasing the possibilities of breast-conserving surgery (BCS) [11]. In this context, letrozole has shown to be more effective than tamoxifen, obtaining higher response and BCS rates following 4 months of preoperative therapy [12,13]. However, less than 60% of patients will respond to this optimal endocrine therapy [14]. To date, only the presence and intensity of hormonal receptors (ER/PgR) are useful tools as predictive markers in clinical practice. Identification of more accurate markers for more efficient patient selection to exclude non-responsive cases remains crucial.
###end p 12
###begin p 13
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 825 833 825 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 927 935 927 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1046 1054 1046 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
Genetic polymorphisms in the CYP19A1 gene have been associated with altered sex hormone levels in serum and urine [15-17], providing an explanation for an elevated risk for BC in relation to estrogen exposure. For example, the tetranucleotide repeat polymorphism in intron 4 (TTTA)n has been associated with BC risk in initial studies [18-22]. The polymorphism rs10046 in the 3' untranslated region (3'-UTR) also showed inconsistent associations with BC risk [23-26] and has also been related with tumor stage [25], circulating sex hormone levels [15], HER2 status and disease free and overall survival [27,28]. rs4646 has been reported to be associated with circulating steroid hormone levels [17] and, as in rs10046, with the HER2 status of the tumor [27]. Hence, it is biologically plausible that the polymorphisms in the CYP19A1 gene may be associated with the response to aromatase inhibitors. Indeed, recently the rs4646 CYP19A1 polymorphism has been associated with letrozole efficacy in advance disease [29]; however, no evidence between CYP19A1 polymorphisms and therapeutic efficacy of aromatase inhibitors in early stage BC has yet been established.
###end p 13
###begin p 14
###xml 61 69 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
In the present study, we perform a genetic analysis of three CYP19A1 polymorphisms in a series of postmenopausal endocrine-sensitive BC patients treated with neoadjuvant letrozole and describe their association both with radiological response at 4 months (RR4M) of treatment and with progression free survival (PFS).
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient selection and DNA samples
###end title 16
###begin p 17
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
We identified a total of 153 postmenopausal patients treated in our institution with letrozole as primary systemic therapy for stage II - III BC between April 1999 and March 2008. Only those cases which met the following criteria were eligible for the study: 1) histological diagnosis of invasive BC by tru-cut or biopsy; 2) positive hormonal receptors status measured by immunohistochemistry (> 10% ER and/or PgR); 3) preserved tumor block; 4) bidimensionally measurable disease by mammogram and/or breast ultrasound; 5) adequate radiological follow-up at 4 months (+/- 14 days); 5) treatment with letrozole (Femara: Novartis Pharma AG, Basel, Switzerland) as neoadjuvant therapy by 2.5 mg/day for a minimum of 4 months in the absence of progression or side effects; and 6) patients able to provide a blood sample.
###end p 17
###begin p 18
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 99 102 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
Finally, 95 patients fulfilled all criteria, were contacted by their physician (AGZ, ALC, ARS, JG, MAC, VG) and agreed to participate on the study. All patients gave their written consent for the use of their DNA for this specific research proposal. In addition, this study was reviewed and approved by the FIVO Science and Ethics Committees.
###end p 18
###begin p 19
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Peripheral blood samples (7 ml) were obtained from these patients and processed for DNA extraction at the Laboratory of Molecular Biology.
###end p 19
###begin p 20
Response to treatment at four months was done using the WHO criteria: complete response (CR) required the complete disappearance of all disease, partial response (PR) was defined as a reduction of >/= 50% in tumor volume and stable disease (SD) was any reduction < 50% in tumor volume. The response evaluation was done by an independent radiologist (JCD).
###end p 20
###begin p 21
###xml 29 36 <span type="species:ncbi:9606">patient</span>
Pre-treatment study included patient characteristics, menopausal status, disease history, histological grade and diagnosis, evaluation of hormone receptor status, HER2 and Ki67 status by immunohistochemical analysis on core-cut biopsies, ECOG performance status and tumor assessment. The clinical data were prospectively reviewed and stored within a specific database.
###end p 21
###begin title 22
Histological and immunohistochemical analysis
###end title 22
###begin p 23
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
Core-cut biopsies were taken with a 14-guage needle before treatment and fixed in neutral buffered formalin for histological studies. The breast tumors were graded according to the modified Bloom and Richardson score on H&E-stained slides [30].
###end p 23
###begin p 24
###xml 418 423 <span type="species:ncbi:9796">horse</span>
###xml 837 842 <span type="species:ncbi:10090">mouse</span>
Four-micrometer sections from embedded blocks were cut on poly-L-lysine-coated slides, and dewaxed, endogenous peroxidase was inhibited with 3% hydrogen peroxide for 30 min. Immunoreactivity was enhanced with antigen retrieval treatment by heating the slides in a microwave oven for 10 min (700 W) in 10 mM sodium citrate buffer pH 7, followed by cooling for 20 min at room temperature. Sections were blocked with 20% horse serum in phosphate-buffer saline (PBS) and incubated with primary antibody for 1 h at room temperature. The incubation time for the secondary antibody and avidin-biotin complexes was 30 min at room temperature. Sections were extensively washed and the immunoreactions developed using DAB (0.05% 3'3' diamino-benzidine in 0.1% hydrogen peroxide). Negative controls included substitution of the primary antibody by mouse ascites or PBS. Slides were counterstained in Mayer hematoxylin, dehydrated, and mounted.
###end p 24
###begin p 25
ER and PgR expression in primary tumor was immunohistochemically evaluated using the anti-ER (clone 6F11) and anti-PgR (clone 1A6) antibodies (Novocastra Laboratories, Newcastle upon Tyne, England) at a dilution of 1:40 and 1:30 respectively. Ki67 expression was also determined using the anti-Ki67 (clone MIB1) antibody (Dako Corp., Carpinteria, CA) at a 1:50 dilution.
###end p 25
###begin p 26
###xml 258 259 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</italic>
###xml 258 259 258 259 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>+</italic></bold>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
HER2 protein expression was immunohistochemically evaluated using the HercepTest Kit (Dako Corp., Carpinteria, CA) according to the manufacturer's protocol. The scoring system was as follows: 0, tumors with no or weak staining in less than 10% of the cells; +, tumors with a faint or barely perceptible membrane staining in more than 10% of cells or with noncircumferential staining; ++, moderate circumferential membrane staining; +++, strong circumferential membrane staining. Scores 0 and + were considered as negative; scores ++ and +++ were considered as positive for HER2 overexpression [31].
###end p 26
###begin title 27
DNA isolation
###end title 27
###begin p 28
###xml 150 153 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
Genomic DNA used for genotyping studies was isolated from peripheral blood mononucleated cells, previously separated by centrifugation with Histopaque(R)-1077 (SIGMA-ALDRICH, LTD Irvine, UK), using the UltraClean DNA Blood Isolation Kit (MO BIO, Carlsbad, CA, USA). DNA integrity was evaluated by the A260/A280 absorbance ratio with a Nanodrop-1000 (Thermo Scientific) spectrophotometer.
###end p 28
###begin title 29
CYP19A1 Genotyping
###end title 29
###begin p 30
###xml 124 131 124 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1</italic>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 258 261 258 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">264</sup>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 669 670 667 668 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The single nucleotide polymorphisms (SNPs) rs10046 (A/G) and rs4646 (C/A) located at the 3'-untranslated region (3'-UTR) of CYP19A1, previously associated with letrozole efficacy in advanced BC [29], and the rs700519 (C/T) in the first base of codon 264 (Arg264Cys), related with low levels of aromatase activity [32], were evaluated. The rs700519 was analyzed by PCR amplification and direct sequencing. Briefly, amplification was carried out in a final volume of 25 mul containing 100 ng genomic DNA, 0.3 muM of forward (5'-CATGAAGTGTAGGGTC-TATGTAAT-3') and reverse (5'-GATCTTTACACACCTCTACACAGT-3') primers, 0.2 mM dNTPs (deoxyribonucleoside triphosphates), 2 mM MgCl2, 1x _Buffer II (Applied Biosystems, New Jersey, USA) and 1 unit AmpliTaq Gold (Applied Biosystems, New Jersey, USA). PCR conditions were 94degreesC for 10 minutes; 35 cycles with denaturation at 94degreesC for 30 seconds, annealing at 52degreesC for 30 seconds, and elongation at 72degreesC for 30 seconds; and a final extension step at 72degreesC for 10 minutes. PCR products were visualized on 1.5% agarose gels containing ethidium bromide and after UV radiation. Purified PCR products were then sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Warrington WA1 4SR, UK) and electrophoresed on a ABI 3130xl Genetic Analyzer (Applied Biosystems). Sequencing analysis was performed with the Sequencing Analysis 5.2 Software (Applied Biosystems).
###end p 30
###begin p 31
Genotyping of the rs10046 and rs4646 polymorphisms were carried out by allelic discrimination using specific TaqMan SNP Genotyping Assays and following the manufacturer's instructions. In brief, 20 mul PCR reactions were carried out containing 10.0 mul TaqMan Universal PCR Master Mix (Applied Biosystems, New Jersey, USA), 20.0 ng DNA template and 1.0 muL TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City CA 94404). The references of selected assays were: C_8234731_1 (rs10046) and C_8234730_1 (rs4646). All assays were performed in 96-well plates including non-template controls. PCR reactions were read on a 7500 Fast Real Time PCR System in end-point mode using the Allelic Discrimination Sequence Detector software (Applied Biosystems).
###end p 31
###begin title 32
Statistical analysis
###end title 32
###begin p 33
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
Statistical analysis was carried out using the SPSS statistical software package (version 15.0.1, SPSS Inc., Chicago, Illinois, USA). A total of 95 patients were included in the analysis. Data on radiological response at the fourth month of induction therapy, progression and survival status, immunohistochemical markers, histological grade, stage and genotype were available for these patients.
###end p 33
###begin p 34
For the statistical analysis we used binary variables reflecting the positivity status of the measures (yes or no) as well as the genotypic status of each polymorphism (homozygous reference or heterozygous/homozygous less frequent). Association with histopathological parameters, all categorical, was also assessed using a chi-square test to determine homogeneity or linear trend for ordinal variables. The significance level was set at 5%.
###end p 34
###begin p 35
###xml 114 116 112 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 134 136 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
Deviations of genotype frequencies from those expected under Hardy-Weinberg equilibrium (HWE) were assessed by chi2 (p > 0.05) tests [33].
###end p 35
###begin p 36
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
To study the impact of the biological factors on progression-free survival (PFS), the Kaplan-Meier proportional risk test (Log Rank) was used [34,35]. PFS was defined as the time interval from the start of treatment to local or distant disease progression. Those patients that reported disease progression during the follow-up were considered as censored, being the data of confirmation of this progression considered in the calculation of PFS. Univariate predictors of PFS were entered into a Cox proportional hazards model using stepwise selection to identify the independent predictors of poor outcome, a confidence interval (CI) of 95% was also considered [36].
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient and tumor characteristics
###end title 38
###begin p 39
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 62 67 <span type="species:ncbi:9606">women</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 777 784 <span type="species:ncbi:9606">patient</span>
Ninety-five stage II-III ER/PgR-positive BC in postmenopausal women treated with letrozole as neoadjuvant therapy were analyzed. The median age of the series was 78.3 years (range: 61.7-89.8). The histopathological and clinical characteristics of the series are summarized in Table 1. As shown, 67 patients presented infiltrating ductal carcinoma (IDC), 16 infiltrating lobular carcinoma (ILC) and the remaining 12 cases corresponded to 9 mucinous carcinomas, 2 tubular carcinomas and one medullar carcinoma. The histological grade was available in only 52 of the IDC due to sample limitations. Most of the cases were stage IIa BC (68.4%), the majority of cases having a T2 tumor (80%). All tumors expressed HR (ER or PgR or both). Considering the whole HR expression for each patient we distinguished two groups of cases: those having low level HR (expressing HR in </= 40% of tumor cells) and those with a high HR expression (> 40% of cells). Ten cases were classified in the first group (10.5%). HER2 and Ki67 expression was also evaluated, 32 cases were HER2 ++/+++ (33.7%) and 32 out of 73 cases analyzed expressed Ki67 (44.4%).
###end p 39
###begin p 40
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Clinical and pathological characteristics of the patients.
###end p 40
###begin p 41
*IDC, Infiltrating ductal carcinoma; ILC, Infiltrating lobular carcinoma; Others (Mucinous, tubular and medullar carcinomas).
###end p 41
###begin p 42
**Hormonal status was considered as </= 40% when either estrogen and progesterone receptors were </= 40%, and as > 40% when at least one of the receptors were > 40%.
###end p 42
###begin p 43
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 485 490 <span type="species:ncbi:9606">women</span>
The median treatment period with letrozole as neoadjuvant therapy was 10.23 months (range: 3.53-85). Response to treatment was evaluated by radiological means (mammogram or ultrasound) at four months of letrozole administration using WHO criteria [37]. A total of 34 partial responses (PR) and one complete response (CR) where achieved, and were classified as responders for the analysis. Hence, the overall radiological response rate at 4 months (RR4M) was 36.8%. On the contrary, 55 women remained with stable disease (SD) and 5 developed progression disease (PD), these all being considered as non-responders.
###end p 43
###begin title 44
CYP19A1 polymorphism analysis
###end title 44
###begin p 45
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
A total of three single nucleotide polymorphisms (SNPs) were evaluated: one located in exon 7 (rs700519) and two in the 3'-UTR region of CYP19A1 (rs10046 and rs4646). Polymorphism references, genotypes, gene and chromosome locations, and frequency distribution of observed genotypes in the series are shown in Table 2. In addition, values for Hardy-Weinberg (HW) [33] equilibrium were estimated for each polymorphism and are also listed in Table 2. Both rs10046 and rs4646 were in HW equilibrium; however, for rs700519 this calculation was not possible as no genetic variant (CT, TT) was observed in any of the analyzed cases.
###end p 45
###begin p 46
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
CYP19A1 polymorphisms and genotype frequencies
###end p 46
###begin p 47
*p > 0.05 is consistent with the Hardy-Weinberg equilibrium; ** Sequence of reference NT_010194.16.
###end p 47
###begin title 48
Analysis between RR4M and clinical, pathological and genotypic parameters
###end title 48
###begin p 49
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
No statistically significant association was found between RR4M and the clinical and pathological parameters (Table 3). However, an overrepresentation of the genetic variants (AC/AA) of the rs4646 polymorphism was observed in the non-responder group (48.3%) compared with the responders (25.7%) (p = 0.03) (Table 3).
###end p 49
###begin p 50
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th </sup>
Association of clinical, pathological and genotypic parameters with radiological response at 4th month of letrozole administration.
###end p 50
###begin title 51
Clinical, pathological, genotypic parameters and progression free survival (PFS)
###end title 51
###begin p 52
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 400 408 <span type="species:ncbi:9606">patients</span>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
The median follow-up of the series was of 40.6 months (range: 4.3-113.8 months). A total of 18 patients (18.9%) reported disease progression during this period (Table 1). Among the analyzed parameters, IIIa-IIIb stages and the non response to letrozole induction therapy were significantly associated with shorter PFS (Table 4; Additional file 1: Supplemental Table S1; Fig. 1). Interestingly, those patients carrying the genetic variants (AC/AA) of rs4646 presented a worse PFS than the patients homozygous for the reference variant (Table 4; Additional file 1: Supplemental Table S1; Fig. 2). Multivariate analysis showed that lymph node involvement [Hazard Ratio (HR) = 4.3 (1.7-11); p = 0.002] and RR4M [HR = 11 (1.5-83); p = 0.012] constituted independent prognostic factors for PFS.
###end p 52
###begin p 53
###xml 111 114 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th </sup>
###xml 0 151 0 151 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kaplan Meier plot showing the progression-free survival with regard the radiological response to letrozole at 4<sup>th </sup>month (RR4M) of the induction therapy</bold>
Kaplan Meier plot showing the progression-free survival with regard the radiological response to letrozole at 4th month (RR4M) of the induction therapy.
###end p 53
###begin p 54
###xml 0 119 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kaplan Meier plot showing the progression-free survival with regard the genetic variants of rs4646 in the global series</bold>
Kaplan Meier plot showing the progression-free survival with regard the genetic variants of rs4646 in the global series.
###end p 54
###begin p 55
Association of clinical, pathological and genotypic parameters with progression free survival (PFS).
###end p 55
###begin title 56
Clinical, pathological, genotypic parameters and PFS according to the surgery status
###end title 56
###begin p 57
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 541 549 <span type="species:ncbi:9606">patients</span>
###xml 603 611 <span type="species:ncbi:9606">patients</span>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
Sixty-five out of the 95 patients (68%) underwent surgery after letrozole induction therapy and no association was observed between the progression status and surgery (Table 1). In fact, 20% of non-surgery cases progressed, while 18.5% of the surgery group experienced progression events (p = 0.861). In addition, no significant differences in terms of PFS were observed between the non-surgery (74.5%) and surgery (60.4%) groups (p = 0.600). However, when we compared clinical, pathological and genetic parameters between the two groups of patients according to surgery status, we observed that 77% of patients of the non-surgery group were over the median age, compared with 37% of the patients from the surgery group (p = 0.00032). Moreover, rs4646 variant (AC/AA) was overrepresented in the non-surgery group (57%) in contrast to the surgery group (32%) (p = 0.024).
###end p 57
###begin p 58
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3A</xref>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
Univariate analysis performed for PFS for each group of patients revealed that in the non-surgery group, RR4M and r4646 where associated with a worse prognosis (Table 5; Additional file 2: Supplemental Table S2). Indeed, the 6 patients who progressed were genetically characterized by the variant rs4646 (AC/AA) (Fig. 3A). However, in the multivariate analysis only the polymorphism rs4646 emerged as an independent prognostic factor although it did not reach statistical significance (p = 0.191).
###end p 58
###begin p 59
###xml 0 154 0 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kaplan Meier plot showing the progression-free survival with regard the genetic variants of rs4646 in the no surgery (A) and surgery group of patients (B)</bold>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Kaplan Meier plot showing the progression-free survival with regard the genetic variants of rs4646 in the no surgery (A) and surgery group of patients (B).
###end p 59
###begin p 60
Association of clinical and genotypic parameters with progression free survival (PFS) according to surgery status.
###end p 60
###begin p 61
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3B</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
In the group of patients operated after letrozole induction, only Ki67 expression and RR4M were associated with worse PFS (Table 5; Additional file 2: Supplemental Table S2), although none of these variables were independent indicators of poor outcome. Contrary to that observed in the non-surgery group, no association of the rs4646 variants with PFS was observed (Fig. 3B).
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 94 102 94 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 253 256 253 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th </sup>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 180 185 <span type="species:ncbi:9606">women</span>
We describe a relationship between the genetic variants (AC/AA) of the rs4646 polymorphism of CYP19A1 and a poor response to neoadjuvant treatment with letrozole in postmenopausal women with ER/PgR [+] BC. The radiological response was measured at the 4th month of letrozole induction, the observed response rate being 36.8%, similar to the radiological response reported in the P024 trial [12].
###end p 63
###begin p 64
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 169 177 169 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 290 298 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 461 469 461 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
At genetic level, mutations in the aromatase gene may lead to a functionally less sensitive aromatase phenotype. Although mutations in the CYP19A1 gene can be generated in vitro, to date no somatic mutation has been found in clinical samples [38]. However, several genetic polymorphisms of CYP19A1 have been reported so far, although the possible functional significance of most of these remains undefined. In the case of BC, population-based studies of common CYP19A1 polymorphisms have generated inconsistent results with regard to their possible association with sex hormone levels, cancer risk, HER2 status or survival [15,19,21,27,28]. No association between the HER2 or hormonal status of either rs10046 or rs4646 was observed in our series.
###end p 64
###begin p 65
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CY19A1 </italic>
###xml 218 226 218 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 617 626 617 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 775 778 775 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">264</sup>
###xml 799 802 799 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">201</sup>
###xml 822 824 822 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">39</sup>
###xml 849 852 849 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">364</sup>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 959 962 959 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">364</sup>
###xml 1006 1010 1006 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">264 </sup>
###xml 1193 1195 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1363 1365 1363 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1520 1522 1520 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1562 1564 1562 1564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1763 1765 1763 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1831 1833 1831 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 1513 1518 <span type="species:ncbi:9606">women</span>
###xml 1752 1760 <span type="species:ncbi:9606">patients</span>
###xml 1820 1828 <span type="species:ncbi:9606">patients</span>
Whether aromatase inhibitor agents interact with the different CY19A1 genotypes has not so far been clearly established. Only three previous studies have attempted to demonstrate the effect of certain polymorphisms in CYP19A1 on the efficacy of aromatase inhibitors. In the first, Fasching et al., in a series of patients treated with hormonal therapy for more than 2 years, did not observe significant differences between the rs700519, rs10046 and rs4646 polymorphisms with therapy. Unfortunately, the type of antihormonal therapy was not recorded for this analysis [27]. In the second study, a population-based and in vitro study, Ma et al. revealed reductions in the functional activity of aromatase for four phenotypes resulting from non-synonymous changes [rs700519 (Arg264Cys), rs28757184 (Thr201Met), rs2236722 (Trp39Arg), and rs56658716 (Met364Thr)] [32]. These authors found that levels or aromatase enzyme activity decreased dramatically for the Thr364, and also observed a slight decrease in Cys264 allozyme activity. They also demonstrated that the mechanism by which non-synonymous SNPs affect the enzymatic activity is a consequence of an alteration in the enzyme protein level [32]. In the same study, these authors reported that these variants had no significant differences in their affinity to the aromatase inhibitors letrozole and exemestane [32]. Interestingly, the polymorphism rs700519 has also been reported as a prognostic factor in a Chinese study, mainly in a subgroup of premenopausal women [28], but not in the Caucasian population [27]. In addition, it is important to note the differences between these two populations regarding the minor allele frequency of rs700519, being only 3.2% for the Caucasian population (1,257 patients) [27], in comparison with 15.1% in the Asian Cohort (1,136 patients) [28]. In our series, the genetic variants of this polymorphism were underrepresented and not found in any of the cases.
###end p 65
###begin p 66
###xml 238 246 238 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1328 1330 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1470 1476 1470 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2D6</italic>
###xml 1606 1612 1606 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2D6</italic>
###xml 1743 1745 1743 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 2096 2098 2096 2098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 2265 2273 2265 2273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 2347 2349 2347 2349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 2462 2464 2462 2464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 708 716 <span type="species:ncbi:9606">patients</span>
###xml 1128 1135 <span type="species:ncbi:9606">patient</span>
###xml 1173 1181 <span type="species:ncbi:9606">patients</span>
###xml 1262 1270 <span type="species:ncbi:9606">patients</span>
###xml 1575 1583 <span type="species:ncbi:9606">patients</span>
###xml 1841 1849 <span type="species:ncbi:9606">patients</span>
The third study evaluated the efficacy of treatment with letrozole in advanced hormone receptor-positive BC patients with respect to two polymorphisms located at the 3'-UTR (rs10046 and rs4646) and one in intron 2 [rs727479 (G/T)] of the CYP19A1 [29]. The authors found that genetic variants of rs4646 were associated with a greater efficacy of letrozole in terms of time to progression. Hence, patients with the variant genotype (AC/AA) had a three times greater time to progression than the patients with the reference genotype (CC). Furthermore, these authors reported that the frequency of the variant alleles for rs4646 was significantly higher in the responder (61%) than in the non-responder group of patients (40%) [29]. These observations clearly differ from those reported in our series, the genotypic variants of rs4646 being more frequently represented in the non-responder group to letrozole after 4 months of induction therapy (48% vs. 26%). In this regard, there are two main issues that could explain the differences between these two studies. First, and independently of the disease stage, are the criteria for patient selection. Whereas in our series the patients were treated with letrozole as a first line, in the study of Colomer et al. the patients had progressed from a previous treatment with tamoxifen [29]. It is well established that tamoxifen metabolism is influenced by the number of mutant alleles of the gene encoding cytochrome P450 2D6 (CYP2D6), because this enzyme affects the levels of endoxifen, the active tamoxifen metabolite. Thus, for patients who are wild type for CYP2D6, the 5-year disease-free survival outcomes are similar to or perhaps even superior with tamoxifen than with aromatase inhibitors [39]. Therefore, previous treatment with tamoxifen could have genetically selected a population of patients more sensitive to letrozole. Secondly, in our study we used constitutive DNA obtained from peripheral blood for the genetic analysis, whereas Colomer et al. performed the genetic study on DNA obtained from the fixed and paraffin-embedded tumors [29]. The polymorphism studies performed on tumor samples are subject to genetic alterations that can affect the chromosomal region of the gene under study. In this way, CYP19A1 is located in the 21.2 region of the long arm of chromosome 15 (15q21.2) [40], and this region has been reported to be a frequent target of allelic imbalance in advanced breast carcinomas [41], and which could affect the frequency distribution of the allelic variants.
###end p 66
###begin p 67
###xml 20 25 <span type="species:ncbi:9606">women</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 361 366 <span type="species:ncbi:9606">women</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
###xml 598 605 <span type="species:ncbi:9606">patient</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
###xml 820 825 <span type="species:ncbi:9606">women</span>
###xml 922 927 <span type="species:ncbi:9606">women</span>
From our series, 65 women underwent surgery after letrozole induction, being age the only difference observed between the operated and non-operated patients. In fact 77% of patients within the non-surgery group were over 78.3 years. We have demonstrated that genetic variants of rs4646 have prognostic value, especially in this group of patients. Indeed, the 6 women who progressed within the group of non-surgery patients were genetically characterized by the variant rs4646 (AC/AA). In this elderly group of patients the decision for undergoing surgery is not always easy and very often both the patient and the clinician opt for a local control of the tumor maintaining the treatment with letrozole. Hence, in this group of patients, in which the tumor is not removed, is where the rs4646 polymorphism identifies the women who progressed, indicating, and despite the small number the cases included in our series, that women with the rs4646 (AC/AA) genotype could benefit from another therapeutic approach.
###end p 67
###begin p 68
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 860 868 <span type="species:ncbi:9606">patients</span>
The regulatory interactions between the ER, growth factor receptors and other kinase signalling pathways could also determine the response to endocrine therapy. In the adjuvant setting, several studies suggest that patients overexpressing HER2 may derive relatively less benefit from endocrine therapy [38]. In the P024 trial, ER [+] tumors that were also EGFR and/or HER2 [+] responded significantly better to letrozole than to tamoxifen (88% vs 21% respectively, P = 0.0004) [13]. The IMPACT study, that confronted tamoxifen with anastrozole, or the preoperative combination of both, observed a similar effect in favour of anastrozole for HER2 [+] tumors (Odds Ratio 58% vs. 22%), although not reaching statistical significance [42]. In our series, as in both randomized trials, no differences in activity were observed relating to HER2 expression among the patients receiving letrozole.
###end p 68
###begin p 69
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1146 1154 <span type="species:ncbi:9606">patients</span>
Biological studies of tissues obtained during neoadjuvant therapy have thrown a different perspective on this issue. Short-term estrogen deprivation leads to profound changes in transcriptional profiles, and these changes can be used as predictive tools. Tumor expression of the proliferation antigen Ki67 after 2 weeks of endocrine treatment (tamoxifen or anastrozole) predicts for clinical response and recurrence-free survival [42]. However, among cases on anastrozole, only 7% did not present a reduction in the Ki67 expression at 2 weeks. In many cases, this reduction in the tumor proliferation rate is only modest and could not be sufficient to determine a resistance to the treatment. As expected, early tumor changes are not limited to proliferation markers, but to other genes directly regulated by ER, including the aromatase itself [43]. Other, currently ongoing, approaches have used gene expression profiling techniques able to predict response to endocrine therapy, but the results obtained so far are inconsistent [43]. In our series, expression of proliferating marker Ki67 constituted a factor of poor prognosis in the group of patients undergoing surgery following letrozole induction therapy, suggesting that this marker could identify tumors with a more aggressive behavior.
###end p 69
###begin title 70
Conclusion
###end title 70
###begin p 71
###xml 80 88 80 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1 </italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 271 276 <span type="species:ncbi:9606">women</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
We have found that genetic variants of the polymorphism rs4646 in the 3'-UTR of CYP19A1 are associated to poor response to letrozole after 4 months induction therapy and to poor outcome of elderly patients without surgery after letrozole administration in postmenopausal women with ER/PgR [+] BC. Although our study would suggest that analysis of rs4646 could improve the clinical management of these patients by facilitating a more individualized therapy, further studies based on larger series are necessary to confirm these findings.
###end p 71
###begin title 72
List of abbreviations
###end title 72
###begin p 73
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP19A1</italic>
3'-UTR: 3'-untranslated region; CYP19A1: aromatase gene; BC: breast cancer; BCS: breast conserving surgery; CR: complete response; DAB: diamino-benzidine; ER: estrogen recetor; HWE: Hardy-Weinberg equilibrium; IDC: infiltrating ductal carcinoma; ILC: infiltrating lobular carcinoma; PR: partial response; PBS: phosphate-buffer saline; PgR: progesterone receptor; PD: progression disease; PFS: progression free survival; RR4M: radiological response at 4 months; SNPs: single nucleotide polymorphisms; SD: stable disease; WHO: World Health Organization.
###end p 73
###begin title 74
Competing interests
###end title 74
###begin p 75
The authors declare that they have no competing interests.
###end p 75
###begin title 76
Authors' contributions
###end title 76
###begin p 77
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 263 266 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
ZGC carried out the molecular genetic studies, participated in the genetic analysis and drafted the manuscript. AGZ reviewed the clinical records of the patients included in the study and drafted the manuscript. AFS performed the genetic analysis. ALlC, ARS, JG, MAC and VG treated most of the patients included in the study and updated the clinical follow-up. AC, SA and ALlB carried out the histopathological and immunohistochemical analysis. JCD performed the radiological evaluation of the study. JC and CVA performed the trucut biopsies and informed to the patients about the study. JALG conceived of the study, performed the statistical analysis and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 77
###begin title 78
Pre-publication history
###end title 78
###begin p 79
The pre-publication history for this paper can be accessed here:
###end p 79
###begin p 80

###end p 80
###begin title 81
Supplementary Material
###end title 81
###begin title 82
Additional file 1
###end title 82
###begin p 83
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S1. </bold>
Table S1. Association of clinical, pathological and genotypic parameters with progression free survival (PFS). This table shows the associations of the clinicopathological and genetic parameters with PFS that have not been statistically significant.
###end p 83
###begin p 84
Click here for file
###end p 84
###begin title 85
Additional file 2
###end title 85
###begin p 86
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S2.</bold>
Table S2. Association of clinical, histopathological and genotypic parameters with progression free survival (PFS) according to surgery status. This table shows the associations of the clinicopathological and genetic parameters with PFS that have not been statistically significant according to surgery status.
###end p 86
###begin p 87
Click here for file
###end p 87
###begin title 88
Acknowledgements
###end title 88
###begin p 89
###xml 30 35 <span type="species:ncbi:28478">Tania</span>
We thank Maria Garcia Flores, Tania Mazcunan and Laura Martinez for their technical assistance.
###end p 89
###begin p 90
This study has been financed by grants GV0A6/256 from the Conselleria d'Empresa Universitat i Ciencia of the Generalitat Valenciana (JALG) and SOLTI 06/01 (ALLC).
###end p 90
###begin article-title 91
Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis
###end article-title 91
###begin article-title 92
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment
###end article-title 92
###begin article-title 93
###xml 180 185 <span type="species:ncbi:9606">human</span>
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer
###end article-title 93
###begin article-title 94
Aromatase activity in adipose tissue from breast quadrants: a link with tumour site
###end article-title 94
###begin article-title 95
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients
###end article-title 95
###begin article-title 96
###xml 80 85 <span type="species:ncbi:9606">women</span>
A prospective study of endogenous estrogens and breast cancer in postmenopausal women
###end article-title 96
###begin article-title 97
###xml 73 78 <span type="species:ncbi:9606">women</span>
Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study
###end article-title 97
###begin article-title 98
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
###end article-title 98
###begin article-title 99
Aromatase inhibitors in breast cancer
###end article-title 99
###begin article-title 100
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
###end article-title 100
###begin article-title 101
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
###end article-title 101
###begin article-title 102
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
###end article-title 102
###begin article-title 103
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
###end article-title 103
###begin article-title 104
###xml 165 170 <span type="species:ncbi:9606">women</span>
Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in posmenopausal women: The IMPACT trial
###end article-title 104
###begin article-title 105
###xml 79 84 <span type="species:ncbi:9606">women</span>
Polymorphisms associated with circulating sex hormone levels in postmenopausal women
###end article-title 105
###begin article-title 106
###xml 128 133 <span type="species:ncbi:9606">women</span>
Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women
###end article-title 106
###begin article-title 107
###xml 121 126 <span type="species:ncbi:9606">women</span>
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women
###end article-title 107
###begin article-title 108
###xml 63 68 <span type="species:ncbi:9606">women</span>
CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women
###end article-title 108
###begin article-title 109
A rare CYP19 (aromatase) variant may increase the risk of breast cancer
###end article-title 109
###begin article-title 110
Polymorphic variation in CYP19 and the risk of breast cancer
###end article-title 110
###begin article-title 111
Aromatase and breast cancer susceptibility
###end article-title 111
###begin article-title 112
CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study
###end article-title 112
###begin article-title 113
Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk
###end article-title 113
###begin article-title 114
A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches
###end article-title 114
###begin article-title 115
Genetic variants of CYP19 (aromatase) and breast cancer risk
###end article-title 115
###begin article-title 116
No association between a single nucleotide polymorphism in CYP19 and breast cancer risk
###end article-title 116
###begin article-title 117
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients
###end article-title 117
###begin article-title 118
Genetic polymorphisms of the CYP19A1 gene and breast cancer survival
###end article-title 118
###begin article-title 119
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
###end article-title 119
###begin article-title 120
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. 
###end article-title 120
###begin article-title 121
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy
###end article-title 121
###begin article-title 122
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human aromatase: gene resequencing and functional genomics
###end article-title 122
###begin article-title 123
The Hardy-Weinberg Law
###end article-title 123
###begin article-title 124
Nonparametric estimation from incomplete observations
###end article-title 124
###begin article-title 125
Asymptomatically efficient rank invariant test procedures
###end article-title 125
###begin article-title 126
Regression models and life tables
###end article-title 126
###begin article-title 127
Reporting results of cancer treatment
###end article-title 127
###begin article-title 128
Mechanisms of resistance to aromatase inhibitors
###end article-title 128
###begin article-title 129
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis
###end article-title 129
###begin article-title 130
###xml 20 25 <span type="species:ncbi:9606">human</span>
Organization of the human aromatase p450 (CYP19) gene
###end article-title 130
###begin article-title 131
Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas
###end article-title 131
###begin article-title 132
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists
###end article-title 132
###begin article-title 133
Molecular response to aromatase inhibitor treatment in primary breast cancer
###end article-title 133

